Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: To PR or not to PR - is not the question

The only thing that will generate investor interest in PTSC is $ and lots of it. Issuing PRs about legal victories or whatever isn't going to do it. Until PTSC can show a steady and significant revenue stream with possible dividends investors are going to look elsewhere. Without significant revenue coming in most investors will see PRs as nothing more than "pumping".

Share
New Message
Please login to post a reply